Tissue-Engineering

Scientists and journalists agree: Tissue engineering is about to become the defining key in medical technology of the 21st century.

TICEBA - Tissue-Engineering

With the help of tissue engineering it will become possible to "repair" body tissue and organs with adult stem cells and thereby restore their natural function or maintain them over longer periods than previously possible.

Up to the end of the 90's, tissue engineering research was regarded by the general public as an unknown quantity. For journalists it was at best a term they had only heard of! Spring 1998 saw the breakthrough:

With the release of the first product of tissue engineering by the FDA, the US Licensing Authority, the revolutionary discipline provided proof of its applicability.

However, this was only the beginning. At a few selected scientific centres worldwide, for example in the USA, practical experiments have already been carried out on reproducing various tissues, organ parts or even whole organs. This procedure is now well on the way to becoming medical normality.

In future, the availability of our own healthy stem cells will be the key factor to take advantage of new, innovative therapies for malignant or degenerative conditions.

Autologous adult stem cells will be needed, since they generate a highly significant advantage with regard to any therapeutic opportunity opening up in the future.

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients infected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter